A Hoffmann-La Roche–sponsored Phase 3 open-label extension study is actively collecting long-term safety and efficacy data on pertuzumab in patients with solid tumors who demonstrated no disease progression in a preceding pertuzumab parent trial. The study is currently active but no longer enrolling.
Hoffmann-La Roche is conducting a single-arm, open-label, multicenter Phase 3 extension study (NCT02320435) to characterize the long-term safety and efficacy profile of pertuzumab in patients with solid tumors who previously participated in a Roche-sponsored pertuzumab clinical trial. Eligible participants are those who had not experienced disease progression at the conclusion of their respective parent study and, per investigator judgment, were deemed likely to derive continued clinical benefit from ongoing pertuzumab therapy.
Enrolled individuals receive pertuzumab either as monotherapy or in combination with trastuzumab or other anticancer agents, mirroring the regimen from their originating trial. Continuation of therapy proceeds until disease progression, unacceptable toxicity, patient or investigator decision to discontinue, non-compliance, death, or sponsor-initiated study termination—whichever occurs first. This design allows for longitudinal capture of real-world durability and tolerability data beyond the confines of time-limited pivotal trials.
The study is currently in an active, non-recruiting status, indicating that the enrolled cohort is being followed but no new participants are being added. As pertuzumab remains a cornerstone of HER2-targeted regimens—particularly in HER2-positive breast and gastric malignancies—data emerging from this extension study may inform clinical decision-making regarding optimal duration of anti-HER2 therapy and long-term adverse event monitoring in this population.
Given the open-label, single-arm design and the heterogeneous solid tumor population drawn from multiple parent studies, comparative efficacy conclusions will be limited. Findings should be interpreted primarily as hypothesis-generating and supportive of long-term safety characterization rather than definitive evidence of sustained benefit.
Key points
- Phase 3 open-label extension study evaluating long-term pertuzumab safety and efficacy in solid tumor patients who completed a prior Roche-sponsored pertuzumab trial without disease progression.
- Pertuzumab is administered as monotherapy or in combination with trastuzumab or other anticancer agents, consistent with each participant's parent study regimen.
- Study is active but no longer enrolling (NCT02320435); ongoing follow-up continues for the existing cohort.
- Primary objective is longitudinal safety surveillance, with efficacy data collected as a secondary endpoint.
- Single-arm, non-randomized design limits comparative efficacy interpretation across the heterogeneous solid tumor population.
Why it matters
Long-term extension data from this trial may help define the safety boundaries and durability of benefit associated with extended pertuzumab-based HER2-targeted therapy, informing decisions about treatment duration in patients with HER2-positive solid tumors who achieve disease control. Oncologists managing such patients should be aware of emerging long-term tolerability signals as this dataset matures.